This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arvat, E. Articles by Ghigo, E. Search for Related Content PubMed PubMed Citation Articles by Arvat, E. Articles by Ghigo, E.

Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing’s Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma¹

Division of Endocrinology, University of Turin, Ancona (G.A., F.M.), and Naples (A.C., G.L.), Italy; and Europeptides (R.D.), Argenteuil, France

Address all correspondence and requests for reprints to: E. Ghigo, M.D., Divisione di Endocrinologia, Ospedale Molinette, C.so Dogliotti 14, 10126 Torino, Italy. E-mail: camanni{at}pianeta.net

We previously reported that in Cushing’s disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing’s syndrome. Our aim was to extend the study about the effects of HEX (2.0 µg/kg, iv) on ACTH and F secretion in 21 patients with CD (3 men and 18 women, 16–68 yr old). Based on magnetic resonance imaging, 15 CD patients had pituitary microadenoma, and 6 had macroadenoma. The results in CD patients were compared with those in 27 normal age-matched controls (NS; 10 men and 17 women, 24–69 yr old). Basal ACTH and F levels in CD were similar in patients with microadenom (mean ± SEM, 78.3 ± 7.2 pg/mL and 237.1 ± 23.6 µg/L, respectively) and macroadenoma (57.4 ± 9.0 pg/mL and 196.9 ± 20.1 µg/L, respectively) and were higher (P < 0.001) than those in NS (17.7 ± 2.0 pg/mL and 115.3 ± 6.7 µg/L, respectively). In microadenoma CD patients, HEX induced marked ACTH and F increases ( peak, mean ± SEM: 261.2 ± 77.6 pg/mL and 226.1 ± 87.2 µg/L, respectively), which were higher (P < 0.04) than those induced by hCRH (45.6 ± 16.9 pg/mL and 84.6 ± 25.7 µg/L, respectively). Moreover, in microadenoma CD patients, the ACTH and F responses to HEX were higher (P < 0.001) than those in NS (18.5 ± 4.0 pg/mL and 36.1 ± 6.8 µg/L, respectively). In macroadenoma CD patients, HEX induced a slight, but significant increase (P < 0.02) in ACTH and F levels (33.9 ± 18.0 pg/mL and 89.6 ± 34.3 µg/L, respectively), which was not significantly different from that elicited by hCRH (20.0 ± 7.0 pg/mL and 54.8 ± 21.3 µg/L, respectively). In macroadenoma CD patients, the ACTH and F responses to HEX and hCRH were, in turn, similar to those in NS.

In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing’s disease with micro-, but not macro- ACTH-secreting pituitary adenoma. This finding agrees with other evidence pointing toward differences in the hormonal behavior between micro- and ACTH-secreting pituitary macroadenomas.

This article has been cited by other articles:

				M. C. Machado, S. Valeria de Sa, M. L. Correa-Giannella, R. R. Giorgi, M. A. A. Pereira, V. A. S Cescato, D. Giannella-Neto, and L. R. Salgado Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients Eur. J. Endocrinol., May 1, 2008; 158(5): 605 - 613. [Abstract] [Full Text] [PDF]

				R. Giordano, A. Picu, U. Pagotto, R. De Iasio, L. Bonelli, F. Prodam, F. Broglio, L. Marafetti, R. Pasquali, M. Maccario, et al. The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease Eur. J. Endocrinol., October 1, 2005; 153(4): 535 - 543. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				G. Arnaldi, A. Angeli, A. B. Atkinson, X. Bertagna, F. Cavagnini, G. P. Chrousos, G. A. Fava, J. W. Findling, R. C. Gaillard, A. B. Grossman, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5593 - 5602. [Abstract] [Full Text] [PDF]

				G. Arnaldi, T. Mancini, B. Kola, G. Appolloni, S. Freddi, C. Concettoni, I. Bearzi, A. Masini, M. Boscaro, and F. Mantero Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5834 - 5840. [Abstract] [Full Text] [PDF]

				A. M. Pereira, M. O. van Aken, H. van Dulken, P. J. Schutte, N. R. Biermasz, J. W. A. Smit, F. Roelfsema, and J. A. Romijn Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5858 - 5864. [Abstract] [Full Text] [PDF]